Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 10/20 | 0.47 |
| ▸ | CYP17A1 | P05093 | 6/20 | 0.47 |
| ▸ | CYP21A2 | P08686 | 6/20 | 0.47 |
| ▸ | WDR5 | P61964 | 1/20 | 0.46 |
| ▸ | HTR6 | P50406 | 1/20 | 0.46 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.45 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.45 |
| ▸ | QPCT | Q16769 | 1/20 | 0.45 |
| ▸ | CYP4Z1 | Q86W10 | 1/20 | 0.45 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL159804 | 0.99 | CYP11B1 (0.47) | CYP11B1CYP17A1CYP21A2WDR5HTR6 | |
| SCHEMBL22399257 | 0.91 | NAMPT (0.51) | CYP11B1CYP17A1CYP21A2HTR6CYP3A4 | |
| SCHEMBL21500647 | 0.84 | CYP11B1 (0.50) | CYP11B1CYP17A1CYP21A2WDR5CYP11B2 | |
| SCHEMBL173715 | 0.83 | NAMPT (0.54) | CYP11B1CYP17A1CYP11B2CYP1A2POLB | |
| SCHEMBL19742865 | 0.81 | CYP11B1 (0.68) | CYP11B1CYP17A1CYP11B2CYP1A2POLB | |
| SCHEMBL28150003 | 0.81 | CA12 (0.51) | HTR6MAPT | |
| SCHEMBL21500648 | 0.80 | NAMPT (0.55) | CYP11B1CYP11B2CYP1A2POLBCYP3A4 | |
| SCHEMBL28148786 | 0.80 | CA12 (0.50) | HTR6MAPT | |
| SCHEMBL21500662 | 0.78 | NAMPT (0.49) | CYP11B1CYP11B2CYP1A2POLBCYP3A4 | |
| SCHEMBL22399266 | 0.78 | CYP11B1 (0.51) | CYP11B1CYP17A1CYP11B2CYP1A2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10772874-B2 | Compounds and compositions for the inhibition of NAMPT | VALO HEALTH, INC. | 2020-09-15 | — | — | US | disclosed |
| EP-2611804-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | Forma TM, LLC. (US) | 2013-07-10 | — | — | EP | disclosed |
| WO-2012031197-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | FORMA THERAPEUTICS, INC. (US) | 2012-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10772874-B2 | Compounds and compositions for the inhibition of NAMPT | NAMPT, NNMT, NQO1 | CYP11B1 455/4885CYP17A1 2580/4885CYP21A2 932/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.